160 related articles for article (PubMed ID: 38519009)
41. Multimodal in vivo and postmortem assessments of tau in Lewy body disorders.
Coughlin DG; Phillips JS; Roll E; Peterson C; Lobrovich R; Rascovsky K; Ungrady M; Wolk DA; Das S; Weintraub D; Lee EB; Trojanowski JQ; Shaw LM; Vaishnavi S; Siderowf A; Nasrallah IM; Irwin DJ; McMillan CT;
Neurobiol Aging; 2020 Dec; 96():137-147. PubMed ID: 33002767
[TBL] [Abstract][Full Text] [Related]
42. Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies.
Brunnström H; Hansson O; Zetterberg H; Londos E; Englund E
Int J Geriatr Psychiatry; 2013 Jul; 28(7):738-44. PubMed ID: 22911491
[TBL] [Abstract][Full Text] [Related]
43. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
[TBL] [Abstract][Full Text] [Related]
44. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer's disease.
de Oliveira FF; Miraldo MC; de Castro-Neto EF; de Almeida SS; Matas SLA; Bertolucci PHF; Naffah-Mazzacoratti MDG
Aging Clin Exp Res; 2023 Aug; 35(8):1741-1752. PubMed ID: 37264166
[TBL] [Abstract][Full Text] [Related]
45. Cerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease.
Mackin RS; Insel P; Zhang J; Mohlenhoff B; Galasko D; Weiner M; Mattsson N
J Alzheimers Dis; 2015; 43(3):1007-16. PubMed ID: 25125463
[TBL] [Abstract][Full Text] [Related]
46. Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.
Vranová HP; Hényková E; Kaiserová M; Menšíková K; Vaštík M; Mareš J; Hluštík P; Zapletalová J; Strnad M; Stejskal D; Kaňovský P
J Neurol Sci; 2014 Aug; 343(1-2):120-4. PubMed ID: 24928081
[TBL] [Abstract][Full Text] [Related]
47. Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study.
Scaricamazza E; Colonna I; Sancesario GM; Assogna F; Orfei MD; Franchini F; Sancesario G; Mercuri NB; Liguori C
Neurol Sci; 2019 Jul; 40(7):1377-1382. PubMed ID: 30903419
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
Andreasen N; Minthon L; Davidsson P; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K
Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440
[TBL] [Abstract][Full Text] [Related]
49. Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging.
Krell-Roesch J; Rakusa M; Syrjanen JA; van Harten AC; Lowe VJ; Jack CR; Kremers WK; Knopman DS; Stokin GB; Petersen RC; Vassilaki M; Geda YE
Alzheimers Dement; 2023 Oct; 19(10):4498-4506. PubMed ID: 35142047
[TBL] [Abstract][Full Text] [Related]
50. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
[TBL] [Abstract][Full Text] [Related]
51. Neuropsychiatric Symptoms in Parkinson's Disease Dementia Are More Similar to Alzheimer's Disease than Dementia with Lewy Bodies: A Case-Control Study.
Chiu PY; Tsai CT; Chen PK; Chen WJ; Lai TJ
PLoS One; 2016; 11(4):e0153989. PubMed ID: 27101140
[TBL] [Abstract][Full Text] [Related]
52. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
53. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
54. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
[TBL] [Abstract][Full Text] [Related]
55. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.
Paterson RW; Slattery CF; Poole T; Nicholas JM; Magdalinou NK; Toombs J; Chapman MD; Lunn MP; Heslegrave AJ; Foiani MS; Weston PSJ; Keshavan A; Rohrer JD; Rossor MN; Warren JD; Mummery CJ; Blennow K; Fox NC; Zetterberg H; Schott JM
Alzheimers Res Ther; 2018 Mar; 10(1):32. PubMed ID: 29558979
[TBL] [Abstract][Full Text] [Related]
56. Differential Vulnerability of Hippocampal Subfields to Amyloid and Tau Deposition in the Lewy Body Diseases.
Ye R; Goodheart AE; Locascio JJ; Peterec E; Properzi M; Thibault EG; Chuba E; Johnson KA; Brickhouse MJ; Touroutoglou A; Growdon JH; Dickerson BC; Gomperts SN
Neurology; 2024 Jun; 102(12):e209460. PubMed ID: 38815233
[TBL] [Abstract][Full Text] [Related]
57. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T
Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286
[TBL] [Abstract][Full Text] [Related]
58. Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.
Sierra M; Gelpi E; Martí MJ; Compta Y
Neuropathol Appl Neurobiol; 2016 Aug; 42(5):451-62. PubMed ID: 26810462
[TBL] [Abstract][Full Text] [Related]
59. Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies.
Slaets S; Le Bastard N; Theuns J; Sleegers K; Verstraeten A; De Leenheir E; Luyckx J; Martin JJ; Van Broeckhoven C; Engelborghs S
J Alzheimers Dis; 2013; 35(1):137-46. PubMed ID: 23364139
[TBL] [Abstract][Full Text] [Related]
60. Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach.
van Steenoven I; Koel-Simmelink MJA; Vergouw LJM; Tijms BM; Piersma SR; Pham TV; Bridel C; Ferri GL; Cocco C; Noli B; Worley PF; Xiao MF; Xu D; Oeckl P; Otto M; van der Flier WM; de Jong FJ; Jimenez CR; Lemstra AW; Teunissen CE
Mol Neurodegener; 2020 Jun; 15(1):36. PubMed ID: 32552841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
